loading
Overview
Strategic Report
Governance
Financial Statements
Company Information
Annual Report and Accounts for the year ended 30 June 2020
Download the PDF of the Annual Report 2020
Dechra is a global specialist veterinary pharmaceuticals and related products business.
Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide.
Our purpose is the sustainable improvement of animal health and welfare
£515.1m
2019: £481.8m
AER: +6.9%
CER: +6.8%
£218.3m
2019: £127.4m
AER: +0.7%
CER: +0.4%
92.19p
2019: 90.01p
AER: +2.4%
CER: +1.7%
34.29p
2019: 31.60p
AER: +8.5%
CER: +8.5%
£52.2m
2019: £39.0m
AER: +33.8%
CER: +33.6%
32.76p
2019: 30.07p
AER: +8.9%
CER: +7.3%
Read more on Financial Performance
Ampharmco integration progressing well, Mirataz acquisition completed in April 2020 and Osurnia completed in July 2020.
CAP performance robust.
FAP growth accelerating.
Numerous product registrations achieved, and significant progress made on Akston and Tri-Solfen.
Read more on Our Strategy
We believe in the capability of our people and our ability to execute our strategy
Ian Page
Chief Executive Officer
Download the PDF of Chief Executive Officer’s Statement
Our existing business performed robustly this year, recovering well from first half supply issues and through the disruption caused by COVID-19
Paul Sandland
Chief Financial Officer
Download the PDF of Financial Review
The sustainable improvement of animal health and welfare
Pipeline Delivery
Portfolio Focus
Geographical Expansion
Acquisition
Manufacturing & Supply Chain
Technology
People
Dedication
Enjoyment
Courage
Honesty
Relationships
Ambition
Our Values, entrepreneurial attitude and agile approach to the way we do things are the backbone of our Culture. We expect our people to make a difference by collaborating with each other and we support them by providing clear guidance on expectations.
Read more on Our Purpose and Strategy
People Impact of COVID-19
Read more on Strategy in Action
Technology Impact of COVID-19
Manufacturing and Supply Chain Impact of COVID-19
The Board takes ultimate responsibility for Corporate Social Responsibility (CSR) and is committed to developing and implementing appropriate policies that create and maintain long term value for shareholders. During the year, our newly formed CSR committee, made up of representatives from across the Group, reviewed the Group's CSR strategy along with the various frameworks for reporting, and published sustainability reports on Dechra, the latter identified reporting gaps where we could have provided more information on our activities.
Our Community
Our Business
Our People
Our Environment
Read More
